US-based biotechnology company Seattle Genetics has announced that it has gained the Health Canada's Notice of Compliance with conditions (NOC/c) for marketing its ADCETRIS ((Brentuximab Vedotin)) drug used in treating two lymphoma ...
Tags: Seattle Genetics, ADCETRIS drug, Health Canada's Notice of Compliance